Blood-based marker opens up perspectives for cancer diagnostics

Medical Xpress

March 6, 2026

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation therapy. Reliable markers that can be used to predict aggressive tumor progression and treatment success at an early stage are still largely lacking.